Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in obesity-related HFpEF with type 2 diabetes
NL-OMON51963Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF), obesity and type 2 diabetes mellitus (T2DM) comparing Semaglutide + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Change in Kansas City Cardiomyopathy Questionnaire clinical summary score and Change in body weight. Started Aug 2021; status: active, not recruiting.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON51963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51963.